Expertise in
24
conditions

Dr. Manmeet S. Ahluwalia

Oncology
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
24
conditions
Baptist Health Miami Cancer Institute
8900 N Kendall Dr, 
Miami, FL 

Overview

Manmeet Ahluwalia is an Oncologist practicing medicine in Miami, Florida.

Dr. Ahluwalia is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Astrocytoma, and Glioma.

He is actively involved in clinical research, co-authoring 297 peer reviewed articles and participating in 27 clinical trials. Dr. Ahluwalia is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

Baptist Health Miami Cancer Institute
8900 N Kendall Dr, Miami, FL 33176

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
Prospective Surgical Study on the Feasibility of Semi-Automated Tissue Collection, Stabilization, Preservation, and Site Transfer - Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Prospective Surgical Study on the Feasibility of Semi-Automated Tissue Collection, Stabilization, Preservation, and Site Transfer - Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Device
Study Phase: Not Applicable
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug, Radiation
Study Drugs: Ruxolitinib, Temozolomide
Study Phase: Phase 1
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Ibrutinib, Temozolomide
Study Phase: Phase 1
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Bevacizumab
Study Phase: Phase 2
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Biological, Device, Other
Study Phase: Phase 2
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
View 9 Less Clinical Trials

297 Total Publications

Applications of transcranial focused ultrasound for primary brain tumors.
Applications of transcranial focused ultrasound for primary brain tumors.
Journal: Neuro-oncology advances
Published: June 12, 2026
Similar Doctors
Expertise in
13
conditions
Dr. Craig H. Moskowitz
Oncology | Hematology
Expertise in
13
conditions
Dr. Craig H. Moskowitz
Oncology | Hematology
Referral may be required
5555 Ponce De Leon Boulevard, Floor 4, 
Coral Gables, FL 
 (4.3 miles away)
305-243-5302
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Moskowitz is an Oncologist and a Hematologist practicing medicine in Coral Gables, Florida. Dr. Moskowitz is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Moskowitz is currently accepting new patients.

Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Expertise in
57
conditions
Dr. Ricardo J. Komotar
Oncology | Neurosurgery
Referral may be required
1295 Northwest 14th Street, 
Miami, FL 
 (10.6 miles away)
305-243-6946
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ricardo Komotar is an Oncologist and a Neurosurgery provider practicing medicine in Miami, Florida. Dr. Komotar is highly rated in 57 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Meningioma, Glioblastoma, Awake Craniotomy, and Posterior Fossa Decompression. Dr. Komotar is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Baptist Hospital Of Miami

8900 N Kendall Dr, 
Miami, FL 
 (0.1 miles away)
786-596-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Yazmin Odia is an Oncologist practicing medicine in Miami, Florida. Dr. Odia is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Glioma, Brain Tumor, Gliomatosis Cerebri, and Astrocytoma. Dr. Odia is currently accepting new patients.

Frequently Asked Questions about Dr. Manmeet S. Ahluwalia

How do I make an appointment with Dr. Manmeet S. Ahluwalia?

You can book an appointment with Dr. Manmeet S. Ahluwalia by calling their office at 786-345-7208. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Manmeet S. Ahluwalia a top-rated expert for Brain Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Manmeet S. Ahluwalia is classified as an Elite expert for Brain Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Manmeet S. Ahluwalia specialize in?

While Dr. Manmeet S. Ahluwalia is a Oncology, they have specific expertise in Brain Tumor, Glioblastoma, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Manmeet S. Ahluwalia participate in research or clinical trials?

Yes. Dr. Manmeet S. Ahluwalia has published 297 articles and abstracts on conditions like Brain Tumor. You can view a list of Dr. Manmeet S. Ahluwalia's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Manmeet S. Ahluwalia accept my insurance?

Dr. Manmeet S. Ahluwalia accepts most major insurance plans, including Cigna and Florida Blue. We recommend calling the office directly at 786-345-7208 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ahluwalia's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile